Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Expression of Lysophosphatidylinositol Signaling-relevant Molecules in Colorectal Cancer

CHIEKO KITAMURA, HIROFUMI SONODA, HIROYUKI ANZAI, YUZO NAGAI, SHINYA ABE, YUICHIRO YOKOYAMA, HIROAKI ISHII, JUNKO KISHIKAWA, SHIGENOBU EMOTO, KOJI MURONO, KAZUHITO SASAKI, KAZUSHIGE KAWAI, HIROAKI NOZAWA and SOICHIRO ISHIHARA
Anticancer Research May 2021, 41 (5) 2349-2355; DOI: https://doi.org/10.21873/anticanres.15009
CHIEKO KITAMURA
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: czecho12q@gmail.com
HIROFUMI SONODA
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROYUKI ANZAI
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUZO NAGAI
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINYA ABE
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUICHIRO YOKOYAMA
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI ISHII
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNKO KISHIKAWA
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIGENOBU EMOTO
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI MURONO
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUHITO SASAKI
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUSHIGE KAWAI
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI NOZAWA
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOICHIRO ISHIHARA
Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Lysophosphatidylinositol (LPI) is a subspecies of the lysophospholipid mediators produced when phospholipase hydrolyzes membrane phosphatidylinositol. Previously, we used mass spectrometry-based lipidomics to demonstrate that LPI is selectively elevated in colorectal cancer (CRC) tissues. Here, we hypothesized that the expression levels of the LPI biosynthetic enzyme and LPI receptor - DDHD domain containing 1 (DDHD1) and G protein-coupled receptor 55 (GPR55), respectively - may be correlated with malignant potential, and we evaluated their roles in the context of CRC. Materials and Methods: Colorectal specimens from 92 CRC patients underwent DDHD1 and GPR55 immunolabeling. Correlation between protein expression levels and clinicopathological variables was examined. Results: Depth of tumor invasion was positively correlated with DDHD1 expression. Regardless of the degree of invasion depth, GPR55 was highly expressed in CRC tissues. Neither DDHD1 nor GPR55 expression levels were associated with disease-free survival. Conclusion: DDHD1 expression is associated with depth of tumor invasion in CRC tissues and may be involved in tumor progression.

Key Words:
  • Colon cancer
  • lysophospholipid
  • lysophosphatidylinositol
  • GPR55
  • DDHD1

Lysophospholipids (LPLs) are generated through membrane phospholipid hydrolysis by phospholipase A1 (PLA1) or A2 (PLA2). Recent studies have revealed that LPLs exhibit significant biological activity as lipid mediators, by signaling through a set of G protein-coupled receptors. In addition, PLA2 comprises a group of enzymes that hydrolyze phospholipids at the sn-2 position to liberate fatty acids and 1-acyl LPLs, which exert various physiological effects and are involved in tumor growth and invasion (1, 2).

Owing to technological improvements in mass spectrometry, this technique is now well-suited to quantify lysophospholipid species in clinical tissues. In a previous study, we used liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) to comprehensively profile the LPLs present in human colorectal cancer (CRC) tissues. That study demonstrated that lysophosphatidylserine (LPS) and lysophosphatidylinositol (LPI) levels were higher in CRC tissues compared to normal tissues (3). Specifically, levels of 1-acyl 18:0 LPI and 1-acyl 18:1 LPI (both produced by PLA2) as well as 2-acyl 20:4 LPI (produced by PLA1) were higher in CRC tissues (3). In recently, similar studies have been reported for the levels of LPI species, which performed mass spectrometry in tissues or bloods of the patients with CRC and inflammatory bowel disease (4, 5). While LPS is reportedly involved in various cellular functions, relatively little is known about the roles of LPI in the context of CRC.

Regarding the role of LPS in CRC, expression of PS-PLA1, (an enzyme that produces LPS) correlates with CRC depth of invasion and hematogenous metastasis (6). We have also previously reported that LPS promotes the migratory capacity of colorectal cancer cell lines via the LPS receptor and the PI3K/Akt pathway (7). In other cancers, LPS also impacts several cellular response functions, including mast cell degranulation (8, 9), lymphocyte proliferation (10), fibroblast migration (11), and neurite outgrowth (12).

The roles of LPLs such as lysophosphatidic acid and sphingosine-1-phosphate (13, 14) in solid cancers are well-established. Regarding the potential role of LPI in cancer, it binds to G protein-coupled receptor 55 (GPR55) (15); high levels of GPR55 can be detected in the spleen, thymus, testis, small intestine, brain, and other organs and the receptor has been suggested to play an important role in immune function (16, 17). Furthermore, analyses of breast cancer and skin squamous cell carcinoma have demonstrated an association between overexpression of GPR55 and cell proliferation (18, 19). However, the roles of LPI, its biosynthetic enzyme and its receptor have not been well evaluated in the context of CRC. Classification of LPI into 1-acyl or 2-acyl species depends on the position at which fatty acids are linked to the glycerol backbone: PLA1 produces 2-acyl LPI, whereas PLA2 produces 1-acyl LPI. Intracellular PLA1 is named DDHD domain containing 1 (DDHD1) and, accordingly, produces 2-acyl LPI. PLA2 is involved in the production of both LPI and other LPLs, and many studies report its association with cancer (1, 2, 20, 21). However, whether a correlation exists between PLA1 and CRC remains unclear.

Since no existing reports have evaluated expression of GPR55 and DDHD1 in human CRC, the present study aimed to clarify whether GPR55 and DDHD1 are involved in the pathophysiology of CRC. Human CRC tissues underwent polyclonal immunolabeling of GPR55 and DDHD1, and correlation between protein expression levels and clinicopathological variables was analyzed.

Materials and Methods

Participants and samples. Patients undergoing surgery for cancer of the colon or rectum (superior to the peritoneal reflection) at the University of Tokyo Hospital between January and December 2012 were recruited. Of a total of 150 enrolled patients, 120 underwent curative surgery (complete resection), including lymph node dissection. Patients diagnosed with ulcerative colitis, familial adenomatous polyposis, multiple CRCs, or another advanced cancer type, and those who underwent emergency surgery, neoadjuvant chemoradiotherapy, or pre-surgical endoscopic mucosal resection were excluded. Surgical specimens were preserved in 10% buffered formalin and embedded in paraffin blocks. Patient records were reviewed for clinicopathological data, and all lesions were staged according to tumor-node-metastasis (TNM) Classification of Malignant Tumor guidelines were provided by the Union for International Cancer Control (UICC, 7th edition) (22). The study protocol was approved by the Research Ethics Committee of the Graduate School of Medicine, University of Tokyo (Tokyo, Japan) (approval no. G3552-8). All participants provided written informed consent. This study was conducted in accordance with the principles laid out in the 1964 Declaration of Helsinki and its subsequent amendments.

Immunohistochemical evaluation. Consecutive 3-μm-thick formalin-fixed, paraffin-embedded sections underwent manual immunohistochemical labeling. Briefly, following deparaffinization and rehydration, endogenous peroxidase activity was blocked using 3% hydrogen peroxidase in methanol for 15 min. Autoclave-assisted heat-induced antigen retrieval was performed in 10 mM sodium citrate buffer (pH 6.0). Following incubation in 5% bovine serum albumin for 30 min to block non-specific binding-sites, slides were incubated overnight at 4°C in the presence of primary antibodies against GPR55 (polyclonal rabbit anti-human; bs-7686R; 1:200 dilution; Bioss Antibodies Inc., Woburn, Massachusetts, USA) and DDHD1 (polyclonal rabbit anti-human; PA5-62070; 1:500 dilution; Thermo Fisher Scientific, Minato-ku, Tokyo, Japan). After rinsing with deionized water, slides were incubated in the presence of a labeled polymer (Histofine®, Simple Stain MAX-PO (Rat), Nichirei Bioscience Inc., Chuo-ku, Tokyo, Japan) for 30 min at room temperature, followed by addition of diaminobenzidine solution for 7 min. A cocktail of Mayer’s/Lillie-Mayer’s hematoxylin (Mayer’s hematoxylin Solution® and Lillie-Mayer’s hematoxylin Solution®, Muto Pure Chemicals Co., LTD, Bunkyo-ku, Tokyo, Japan) was used as a counterstain. Finally, sections were dehydrated by means of exposure to progressively increasing percentages of ethanol, and were then incubated in xylene prior to mounting.

Slides were independently evaluated at a final magnification of 200× and immunolabeling intensity of cancer cells was classified into four grades: negative, weak, moderate, and strong according to a previous report (6) (Figures 1 and 2). Sections consisting of >50% moderate- or strong-grade cells were classified as GPR55-high/DDHD1-high, while those consisting of ≤50% of such cells were classified as GPR55-low/DDHD1-low. Each section was assessed by two independent observers blinded to clinical findings.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Colorectal cancer sections immunostained by a polyclonal antibody against human G protein-coupled receptor 55 (GPR55). GPR55 staining was mainly observed in cancerous cell membranes (relative to normal epithelia and stromal cells). The immunostaining intensity was classified into four grades, as following: negative, weak, moderate, and strong. Scale bar=200 μm.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Colorectal cancer sections immunostained by a polyclonal antibody against human DDHD domain containing 1 (DDHD1). DDHD1 staining was mainly observed in the cytoplasm of cancerous cells, which generally exhibited more intense staining for this molecule (relative to normal epithelia and stromal cells). The immunostaining intensity was classified into four grades, as following: negative, weak, moderate, and strong. Scale bar=200 μm.

Statistical analysis. For correlation of GPR55 and DDHD1 expression levels with patient clinicopathological features, unpaired t-test was used for comparing continuous variables, and the chi-square test was employed for comparing categorical data.

To determine prognostic value of GPR55 and DDHD1 expression levels, association of section grade with disease-free survival (DFS) rates of 92 patients who had undergone curative surgery was analyzed using the Kaplan-Meier method and log-rank test. All statistical analyses were performed using JMP Pro version 15.0.0 (SAS Institute, Cary, NC, USA). Associations were considered significant at p<0.05.

Results

Patient and lesion characteristics. Clinicopathological features are shown in Table I. There were 53 male and 39 female patients, with a median age at surgery of 67.5 years (range=38-90). Thirty-eight patients (41%) had right-sided colon cancers, while 54 patients (59%) had left-sided colon and upper rectum cancers. Histopathological analysis identified the tumor types carried by 75 patients as differentiated adenocarcinoma. The values for T1-2, T3-T4a were 22% and 78%, respectively. The mean tumor diameter was 45.6±24.4 mm. Lymphatic invasion, venous invasion, and lymph node metastasis were apparent in 33%, 70%, and 38% of the patients, respectively.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient clinicopathological characteristics.

Immunohistochemistry and section grading. Staining for GPR55 was most intense in cancer cell membranes (relative to normal epithelia and stromal cells). Staining for DDHD1 was observed mainly in the cytoplasm of cancer cells, which generally exhibited more intense staining for this molecule (relative to normal epithelia and stromal cells). Among 92 cases, 77 were graded as GPR55-high, 15 were graded as GPR55-low, 69 were graded as DDHD1-high, and 23 were graded as DDHD1-low.

Correlation of GPR55 and DDHD1 expression with clinicopathological variables. Associations between GPR55 expression levels and clinicopathological variables are shown in Table II. There were no significant differences in patient characteristics, tumor location or pathological features between the two groups.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Univariate analysis of the association between clinicopathological variables and G protein-coupled receptor 55 (GPR55) immunostaining.

Results of univariate analyses of associations between DDHD1 expression levels and clinicopathological variables are shown in Table III. High levels of DDHD1 expression were observed in patients with advanced tumor depth (p=0.03). However, no significant correlation was observed between DDHD1 expression and any other clinicopathological variable.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Univariate analysis of the association between clinicopathological variables and DDHD domain containing 1 (DDHD1) immunostaining.

Prognostic value of GPR55 and DDHD1 expression levels in patients with CRC. The DFS rate following curative surgery was not associated with the expression levels of either GPR55 or DDHD1 (five-year DFS rates for GPR55-low and -high groups, respectively: 78.0% and 67.0%, p=0.89; five-year DFS rates for DDHD1-low and -high groups, respectively: 77.0% and 70.0%, p=0.29) (Figures 3 and 4). The commonest sites of recurrence were the liver and lymph nodes (five patients per group), followed by the peritoneum (three patients) and local recurrence (two patients).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

The disease-free survival (DFS) rate for the 92 patients who underwent curative surgery, as evaluated by the log-rank test. The continuous line indicates the DFS curve of the GPR55-high group and the dashed line that of the GPR55-low group.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

The disease-free survival (DFS) rate for the 92 patients who underwent curative surgery, as evaluated by the log-rank test. The continuous line indicates the DFS curve of the DDHD1-high group and the dashed line that of the DDHD1-low group.

Discussion

Our previous work examining human CRC tissue metabolism via LC-MS/MS demonstrated higher levels of LPI and LPS than those in normal tissues (3). Specifically, levels of 1-acyl 18:0 LPI and 1-acyl 18:1 LPI (both produced by PLA2) as well as 2-acyl 20:4 LPI (produced by PLA1) were higher in CRC tissues (3). While LPS is reportedly involved in various cellular functions, relatively little is known about the roles of LPI in the context of CRC. In addition, although PLA2 is known to promote CRC (23), knowledge regarding the role of PLA1 in the context of CRC is lacking. To explore whether CRC patient clinicopathological factors were associated with the expression of molecules involved in LPI signaling, correlations between DDHD1 and GPR55 expression patterns and CRC clinicopathological features were elucidated.

Results demonstrated a significant positive correlation between depth of tumor invasion and DDHD1 expression. Previously, DDHD1 (the enzyme which preferentially generates 2-acyl LPI species) was known as phosphatidic acid-preferring PLA1 (PA-PLA1) (24). This enzyme is believed to hydrolyze cell membrane phosphatidylinositols to generate arachidonic acid-containing 2-acyl LPI (25). It has been reported that DDHD1 enhances proliferation and survival of CRC cells: its down-regulation decreases colon cancer cell viability and increases the rate of apoptosis of these cells in vitro. Furthermore, silencing DDHD1 inhibits MERK/ERK and PI3K/Akt signaling, and DDHD1 over-expression supports in vitro and in vivo cancer cell growth by stimulating ERK1/2 signaling (26). In conjunction with results of the present study, these findings suggest that up-regulation of DDHD1 may be involved in CRC progression.

Similarly, GPR55 is reportedly involved in the pathogenesis of neoplasia (27). In a murine model of colitis-associated CRC, GPR55–/– mice exhibited fewer tumors and lower total tumor areas than their wild-type counterparts. In addition, GPR55 up-regulation in CRC patients is associated with lower relapse-free survival rates (28). In contrast, the present study does not demonstrate a significant correlation between GPR55 over-expression and clinicopathological factors or clinical outcome. Results must be validated in larger cohorts, using orthogonal methods.

However, preliminary data indicate that while GPR55 expression in adenoma tissues is nearly absent (data not shown) and that GPR55 is expressed in CRC tissue samples in 77 of 92 patients (83.7%, Table II). It remains possible that expression of GPR55 becomes up-regulated during progression from adenoma to carcinoma, whether or not this is causally linked to pathogenesis. Further studies are required to evaluate GPR55 and DDHD1 expression dynamics during adenoma to carcinoma progression. As the bioactivity of 2-acyl LPI is markedly higher than that of other LPI species, this species may be preferentially involved in GPR55-mediated signal transduction (29).

In conclusion, the present study demonstrated that depth of tumor invasion is positively correlated with DDHD1 expression, suggesting that the DDHD1-LPI-GPR55 axis may play a role in the progression of CRC.

Acknowledgements

This research is supported by Grants-in-Aid for Scientific Research (C: grant number; 18K07194, C: grant number; 19K09114, C: grant number; 19K09115, C: grant number; 20K09051, Challenging Research (Exploratory): grant number; 20K21626) from Japan Society for the promotion of Science. This research is supported by the Project for Cancer Research and Therapeutic Evolution (P-CREATE), grant number: JP 19cm0106502 from the Japan Agency for Medical Research and Development (AMED).

  • Received February 18, 2021.
  • Revision received March 23, 2021.
  • Accepted March 26, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Kazama S,
    2. Kitayama J,
    3. Hiyoshi M,
    4. Taketomi Y,
    5. Murakami M,
    6. Nishikawa T,
    7. Tanaka T,
    8. Tanaka J,
    9. Kiyomatsu T,
    10. Kawai K,
    11. Hata K,
    12. Yamaguchi H,
    13. Nozawa H,
    14. Ishihara S,
    15. Sunami Eand
    16. Watanabe T
    : Phospholipase A2 group III and group X have opposing associations with prognosis in colorectal cancer. Anticancer Res 35(5): 2983-2990, 2015. PMID: 25964585.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Hiyoshi M,
    2. Kitayama J,
    3. Kazama S,
    4. Taketomi Y,
    5. Murakami M,
    6. Tsuno NH,
    7. Hongo K,
    8. Kaneko M,
    9. Sunami E and
    10. Watanabe T
    : The expression of phospholipase A2 group X is inversely associated with metastasis in colorectal cancer. Oncol Lett 5(2): 533-538, 2013. PMID: 23420493. DOI: 10.3892/ol.2012.1067
    OpenUrlCrossRefPubMed
  3. ↵
    1. Kitamura C,
    2. Sonoda H,
    3. Nozawa H,
    4. Kano K,
    5. Emoto S,
    6. Murono K,
    7. Kaneko M,
    8. Hiyoshi M,
    9. Sasaki K,
    10. Nishikawa T,
    11. Shuno Y,
    12. Tanaka T,
    13. Hata K,
    14. Kawai K,
    15. Aoki J and
    16. Ishihara S
    : The component changes of lysophospholipid mediators in colorectal cancer. Tumour Biol 41(5): 1010428319848616, 2019. PMID: 31106679. DOI: 10.1177/1010428319848616
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wang Y,
    2. Hinz S,
    3. Uckermann O,
    4. Hönscheid P,
    5. von Schönfels W,
    6. Burmeister G,
    7. Hendricks A,
    8. Ackerman JM,
    9. Baretton GB,
    10. Hampe J,
    11. Brosch M,
    12. Schafmayer C,
    13. Shevchenko A and
    14. Zeissig S
    : Shotgun lipidomics-based characterization of the landscape of lipid metabolism in colorectal cancer. Biochim Biophys Acta Mol Cell Biol Lipids 1865(3): 158579, 2020. PMID: 31794862. DOI: 10.1016/j.bbalip.2019.158579
    OpenUrlCrossRefPubMed
  5. ↵
    1. Grill M,
    2. Högenauer C,
    3. Blesl A,
    4. Haybaeck J,
    5. Golob-Schwarzl N,
    6. Ferreirós N,
    7. Thomas D,
    8. Gurke R,
    9. Trötzmüller M,
    10. Köfeler HC,
    11. Gallé B and
    12. Schicho R
    : Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer. Sci Rep 9(1): 2358, 2019. PMID: 30787385. DOI: 10.1038/s41598-019-38865-4
    OpenUrlCrossRefPubMed
  6. ↵
    1. Iida Y,
    2. Sunami E,
    3. Yamashita H,
    4. Hiyoshi M,
    5. Ishihara S,
    6. Yamaguchi H,
    7. Inoue A,
    8. Makide K,
    9. Tsuno NH,
    10. Aoki J,
    11. Kitayama J and
    12. Watanabe T
    : Phosphatidylserine-specific phospholipase A1 (PS-PLA1) expression in colorectal cancer correlates with tumor invasion and hematogenous metastasis. Anticancer Res 35(3): 1459-1464, 2015. PMID: 25750298.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Iida Y,
    2. H Tsuno N,
    3. Kishikawa J,
    4. Kaneko K,
    5. Murono K,
    6. Kawai K,
    7. Ikeda T,
    8. Ishihara S,
    9. Yamaguchi H,
    10. Sunami E,
    11. Kitayama J,
    12. Yatomi Y and
    13. Watanabe T
    : Lysophosphatidylserine stimulates chemotactic migration of colorectal cancer cells through GPR34 and PI3K/Akt pathway. Anticancer Res 34(10): 5465-5472, 2014. PMID:25275042.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Martin TW and
    2. Lagunoff D
    : Interactions of lysophospholipids and mast cells. Nature 279(5710): 250-252, 1979. PMID: 86956. DOI: 10.1038/279250a0
    OpenUrlCrossRefPubMed
  9. ↵
    1. Smith GA,
    2. Hesketh TR,
    3. Plumb RW and
    4. Metcalfe JC
    : The exogenous lipid requirement for histamine release from rat peritoneal mast cells stimulated by concanavalin A. FEBS Lett 105(1): 58-62, 1979. PMID: 90622. DOI: 10.1016/0014-5793(79)80887-x
    OpenUrlCrossRefPubMed
  10. ↵
    1. Bellini F and
    2. Bruni A
    : Role of a serum phospholipase A1 in the phosphatidylserine-induced T cell inhibition. FEBS Lett 316(1): 1-4, 1993. PMID: 8422930. DOI: 10.1016/0014-5793(93)81724-e
    OpenUrlCrossRefPubMed
  11. ↵
    1. Lee SY,
    2. Lee HY,
    3. Kim SD,
    4. Jo SH,
    5. Shim JW,
    6. Lee HJ,
    7. Yun J and
    8. Bae YS
    : Lysophosphatidylserine stimulates chemotactic migration in U87 human glioma cells. Biochem Biophys Res Commun 374(1): 147-151, 2008. PMID: 18616930. DOI: 10.1016/j.bbrc.2008.06.117
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lourenssen S and
    2. Blennerhassett MG
    : Lysophosphatidylserine potentiates nerve growth factor-induced differentiation of PC12 cells. Neurosci Lett 248(2): 77-80, 1998. PMID: 9654346. DOI: 10.1016/s0304-3940(98)00275-4
    OpenUrlCrossRefPubMed
  13. ↵
    1. Uranbileg B,
    2. Nishikawa T,
    3. Ikeda H,
    4. Kurano M,
    5. Sato M,
    6. Saigusa D,
    7. Aoki J,
    8. Watanabe T and
    9. Yatomi Y
    : Evidence suggests sphingosine 1-phosphate might be actively generated, degraded, and transported to extracellular spaces with increased S1P2 and S1P3 expression in colon cancer. Clin Colorectal Cancer 17(2): e171-e182, 2018. PMID: 29223361. DOI: 10.1016/j.clcc.2017.11.004
    OpenUrlCrossRefPubMed
  14. ↵
    1. Shida D,
    2. Fang X,
    3. Kordula T,
    4. Takabe K,
    5. Lépine S,
    6. Alvarez SE,
    7. Milstien S and
    8. Spiegel S
    : Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res 68(16): 6569-6577, 2008. PMID: 18701480. DOI: 10.1158/0008-5472.CAN-08-0411
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Oka S,
    2. Nakajima K,
    3. Yamashita A,
    4. Kishimoto S and
    5. Sugiura T
    : Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362(4): 928-934, 2007. PMID: 17765871. DOI: 10.1016/j.bbrc.2007.08.078
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ryberg E,
    2. Larsson N,
    3. Sjögren S,
    4. Hjorth S,
    5. Hermansson NO,
    6. Leonova J,
    7. Elebring T,
    8. Nilsson K,
    9. Drmota T and
    10. Greasley PJ
    : The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152(7): 1092-1101, 2007. PMID: 17876302. DOI: 10.1038/sj.bjp.0707460
    OpenUrlCrossRefPubMed
  17. ↵
    1. Oka S,
    2. Kimura S,
    3. Toshida T,
    4. Ota R,
    5. Yamashita A and
    6. Sugiura T
    : Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147(5): 671-678, 2010. PMID: 20051382. DOI: 10.1093/jb/mvp208
    OpenUrlCrossRefPubMed
  18. ↵
    1. Andradas C,
    2. Blasco-Benito S,
    3. Castillo-Lluva S,
    4. Dillenburg-Pilla P,
    5. Diez-Alarcia R,
    6. Juanes-García A,
    7. García-Taboada E,
    8. Hernando-Llorente R,
    9. Soriano J,
    10. Hamann S,
    11. Wenners A,
    12. Alkatout I,
    13. Klapper W,
    14. Rocken C,
    15. Bauer M,
    16. Arnold N,
    17. Quintanilla M,
    18. Megías D,
    19. Vicente-Manzanares M,
    20. Urigüen L,
    21. Gutkind JS,
    22. Guzmán M,
    23. Pérez-Gómez E and
    24. Sánchez C
    : Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget 7(30): 47565-47575, 2016. PMID: 27340777. DOI: 10.18632/oncotarget.10206
    OpenUrlCrossRefPubMed
  19. ↵
    1. Zhou XL,
    2. Guo X,
    3. Song YP,
    4. Zhu CY and
    5. Zou W
    : The LPI/GPR55 axis enhances human breast cancer cell migration via HBXIP and p-MLC signaling. Acta Pharmacol Sin 39(3): 459-471, 2018. PMID: 29188802. DOI: 10.1038/aps.2017.157
    OpenUrlCrossRefPubMed
  20. ↵
    1. Miki Y,
    2. Kidoguchi Y,
    3. Sato M,
    4. Taketomi Y,
    5. Taya C,
    6. Muramatsu K,
    7. Gelb MH,
    8. Yamamoto K and
    9. Murakami M
    : Dual roles of group IID phospholipase A2 in inflammation and cancer. J Biol Chem 291(30): 15588-15601, 2016. PMID: 27226632. DOI: 10.1074/jbc.M116.734624
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Yamashita S,
    2. Ogawa M,
    3. Sakamoto K,
    4. Abe T,
    5. Arakawa H and
    6. Yamashita J
    : Elevation of serum group II phospholipase A2 levels in patients with advanced cancer. Clin Chim Acta 228(2): 91-99, 1994. PMID: 7988039. DOI: 10.1016/0009-8981(94)90280-1
    OpenUrlCrossRefPubMed
  22. ↵
    1. Sobin LH,
    2. Gospodarowicz MK and,
    3. Wittekind Ch
    : International Union against Cancer, ebrary Inc: TNM classification of malignant tumours. 7th ed: Wiley-Blackwell, 2009.
  23. ↵
    1. Murase R,
    2. Taketomi Y,
    3. Miki Y,
    4. Nishito Y,
    5. Saito M,
    6. Fukami K,
    7. Yamamoto K and
    8. Murakami M
    : Group III phospholipase A2 promotes colitis and colorectal cancer. Sci Rep 7(1): 12261, 2017. PMID: 28947740. DOI: 10.1038/s41598-017-12434-z
    OpenUrlCrossRefPubMed
  24. ↵
    1. Higgs HN,
    2. Han MH,
    3. Johnson GE and
    4. Glomset JA
    : Cloning of a phosphatidic acid-preferring phospholipase A1 from bovine testis. J Biol Chem 273(10): 5468-5477, 1998. PMID: 9488669. DOI: 10.1074/jbc.273.10.5468
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Yamashita A,
    2. Kumazawa T,
    3. Koga H,
    4. Suzuki N,
    5. Oka S and
    6. Sugiura T
    : Generation of lysophosphatidylinositol by DDHD domain containing 1 (DDHD1): Possible involvement of phospholipase D/phosphatidic acid in the activation of DDHD1. Biochim Biophys Acta 1801(7): 711-720, 2010. PMID: 20359546. DOI: 10.1016/j.bbalip.2010.03.012
    OpenUrlCrossRefPubMed
  26. ↵
    1. Raimondo S,
    2. Cristaldi M,
    3. Fontana S,
    4. Saieva L,
    5. Monteleone F,
    6. Calabrese G,
    7. Giavaresi G,
    8. Parenti R and
    9. Alessandro R
    : The phospholipase DDHD1 as a new target in colorectal cancer therapy. J Exp Clin Cancer Res 37(1): 82, 2018. PMID: 29653539. DOI: 10.1186/s13046-018-0753-z
    OpenUrlCrossRefPubMed
  27. ↵
    1. Falasca M and
    2. Corda D
    : Elevated levels and mitogenic activity of lysophosphatidylinositol in k-ras-transformed epithelial cells. Eur J Biochem 221(1): 383-389, 1994. PMID: 8168525. DOI: 10.1111/j.1432-1033.1994.tb18750.x
    OpenUrlCrossRefPubMed
  28. ↵
    1. Hasenoehrl C,
    2. Feuersinger D,
    3. Sturm EM,
    4. Bärnthaler T,
    5. Heitzer E,
    6. Graf R,
    7. Grill M,
    8. Pichler M,
    9. Beck S,
    10. Butcher L,
    11. Thomas D,
    12. Ferreirós N,
    13. Schuligoi R,
    14. Schweiger C,
    15. Haybaeck J and
    16. Schicho R
    : G protein-coupled receptor GPR55 promotes colorectal cancer and has opposing effects to cannabinoid receptor 1. Int J Cancer 142(1): 121-132, 2018. PMID: 28875496. DOI: 10.1002/ijc.31030
    OpenUrlCrossRefPubMed
  29. ↵
    1. Oka S,
    2. Toshida T,
    3. Maruyama K,
    4. Nakajima K,
    5. Yamashita A and
    6. Sugiura T
    : 2-Arachidonoyl-sn-glycero-3-phosphoinositol: A possible natural ligand for GPR55. J Biochem 145(1): 13-20, 2009. PMID: 18845565. DOI: 10.1093/jb/mvn136
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (5)
Anticancer Research
Vol. 41, Issue 5
May 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Expression of Lysophosphatidylinositol Signaling-relevant Molecules in Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Expression of Lysophosphatidylinositol Signaling-relevant Molecules in Colorectal Cancer
CHIEKO KITAMURA, HIROFUMI SONODA, HIROYUKI ANZAI, YUZO NAGAI, SHINYA ABE, YUICHIRO YOKOYAMA, HIROAKI ISHII, JUNKO KISHIKAWA, SHIGENOBU EMOTO, KOJI MURONO, KAZUHITO SASAKI, KAZUSHIGE KAWAI, HIROAKI NOZAWA, SOICHIRO ISHIHARA
Anticancer Research May 2021, 41 (5) 2349-2355; DOI: 10.21873/anticanres.15009

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Expression of Lysophosphatidylinositol Signaling-relevant Molecules in Colorectal Cancer
CHIEKO KITAMURA, HIROFUMI SONODA, HIROYUKI ANZAI, YUZO NAGAI, SHINYA ABE, YUICHIRO YOKOYAMA, HIROAKI ISHII, JUNKO KISHIKAWA, SHIGENOBU EMOTO, KOJI MURONO, KAZUHITO SASAKI, KAZUSHIGE KAWAI, HIROAKI NOZAWA, SOICHIRO ISHIHARA
Anticancer Research May 2021, 41 (5) 2349-2355; DOI: 10.21873/anticanres.15009
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Enhanced DNA Double-strand Break Induction by Carbon Ions Under Intratumoral Hypoxia
  • C-myc Oncogene Numerical Imbalances Analysis in Laryngeal Squamous Cell Carcinoma
  • Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
Show more Experimental Studies

Similar Articles

Keywords

  • colon cancer
  • lysophospholipid
  • lysophosphatidylinositol
  • GPR55
  • DDHD1
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire